Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis

Kodai Kawamura*, Kazuya Ichikado, Makoto Takaki, Yoshihiko Sakata, Yuko Yasuda, Naoki Shingu, Aoi Tanaka, Jyunpei Hisanaga, Yoshitomo Eguchi, Keisuke Anan, Tatuya Nitawaki and Moritaka Suga

Abstract
Purpose: Acute respiratory distress syndrome is a life-threatening form of respiratory failure without an established pharmacological treatment. Recently, macrolides have been found to be beneficial in cases of acute lung injury, but evidence is limited.

Materials and methods: This single-centre retrospective cohort evaluation of hospitalized patients with sepsis-associated acute respiratory distress syndrome aimed to assess the impact of azithromycin on clinical outcomes by using a propensity score analysis. All data were collected prospectively as part of ongoing research on high-resolution computed tomography of acute respiratory distress syndrome. The primary outcome was 60-day mortality; the secondary outcome was the number of ventilator-free days.

Results: Twenty-nine of 125 patients with sepsis-associated acute respiratory distress syndrome (23.2%) received azithromycin within 24 h after acute respiratory distress syndrome diagnosis. After adjusting for potentially confounding covariates, azithromycin use was associated with lower 60-day mortality (hazard ratio, 0.31; 95% confidence interval, 0.11–0.82; P = 0.02) and a shorter time to successful discontinuation of mechanical ventilation.

Conclusions: Azithromycin use was associated with decreased mortality and ventilator dependency in patients with sepsis-associated acute respiratory distress syndrome. Further well-designed prospective studies are needed.

Keywords: ARDS, Azithromycin, Macrolide, Prognosis, Propensity score, Ventilator-free days

Background
Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure that affects a heterogeneous population of critically ill patients. Although overall mortality appears to be decreasing in recent years because of improvements in supportive care, the mortality rate from ARDS is approximately 30–40%, and therefore is still high (Rubenfeld et al. 2005; Zambon and Vincent 2008; Force et al. 2012). At present, there is no proven effective pharmacological therapy for ARDS.

Macrolides have immunomodulatory effects in addition to antimicrobial effects. Macrolides have been shown to reduce mortality in many acute lung injury animal models (Tamaoki 2004; Sato et al. 1998; Amado-Rodriguez et al. 2013). In humans, Walkey and Wiener (2012) recently proposed that macrolides may benefit patients with acute lung injury. Walkey reported that the most commonly administered macrolide was erythromycin, followed by azithromycin (40%) in their registry.

Until 2011, erythromycin was the only macrolide that could be used by intravenous injection in Japan, but erythromycin has many side effects and drug
interactions, so we did not routinely use intravenous erythromycin in daily clinical practice. In cases of severe pneumonia, we have used quinolone with beta-lactam antibiotics. Intravenous azithromycin has been approved for clinical use since September 2011 in Japan. Azithromycin is safer and easier to use than erythromycin, and since the publication of Walkey’s report, we routinely use azithromycin for patient with acute respiratory failure from July 2012.

Until now, to our best knowledge, there is no evidence except for Walkey’s report regarding the impact of azithromycin on clinical outcomes in patients with sepsis-associated ARDS.

Therefore, we conducted this retrospective observational study to assess the impact of intravenous azithromycin administration on clinical outcomes in patients with sepsis-associated ARDS by using a propensity score analysis.

Methods

Study subjects and design

We performed a retrospective cohort study of patients with ARDS who underwent intensive care during the period from October 2004 to April 2015 at a tertiary academic teaching hospital in Kumamoto, Japan.

This protocol (IRB no. 289) was approved by the Institutional Review Board at Saiseikai Kumamoto Hospital. Written informed consent was obtained from all subjects or surrogates in accordance with the Declaration of Helsinki. If patients were minors, we obtained written informed consent from legal guardians on behalf of the minors.

The primary outcome was 60-day mortality. Additionally, the duration of mechanical ventilation and predictors of 60-day mortality were evaluated.

All data were collected prospectively as a part of ongoing research on high-resolution computed tomography (HRCT) scores of ARDS patients [portions of these results were previously published (Ichikado et al. 2012)]. All patients were directly admitted to the intensive care unit from the emergency department.

The following patients were excluded: those under 15 years of age, those being treated with anticancer drugs or radiation, unsuitable cases such as those involving hematologic disease, and those in the terminal stage of advanced cancer.

Demographics, clinical features, clinical data on admission, and HRCT data were obtained for all patients within 24 h of admission.

ARDS was defined on the basis of the Berlin definition (Force et al. 2012) of ARDS (between 2013 and 2015) and the American–European consensus conference on ARDS (Bernard et al. 1994) (between 2004 and 2012). Patients diagnosed based on the American–European consensus conference definition were re-evaluated to determine whether they met the Berlin definition. All patients were treated using a lung-protective strategy designed by the ARDS Network and according to clinical practical guidelines for acute lung injury and ARDS published by the Japanese Respiratory Society (2010). Sepsis was defined on the basis of the American College of Chest Physicians/Society of Critical Care Medicine criteria (Bone et al. 1992). We divided sepsis into two categories: pulmonary and non-pulmonary.

Interventions

Before June 2012, there was no patient with sepsis associated ARDS who treated with macrolide. Since July 2012, we use intravenous azithromycin for patients with sepsis associated ARDS within 24 h of ARDS diagnosis. Azithromycin therapy was continued for 5 days if there was no reason to cease administration, such as side effects and arrhythmia, but discontinuation of azithromycin was at the discretion of the attending physician. We did not have specific information about whether patients were treated with oral or intravenous macrolides before admission. No patient was treated with extracorporeal membrane oxygenation therapy in this study cohort.

Statistical analysis

We summarized baseline characteristics by using percentages for categorical variables and medians and interquartile ranges (IQRs) for continuous variables; comparisons between groups were performed using the Mann–Whitney rank-sum test and Fisher’s exact test, respectively. Survival time in days is reported as the median (95 % confidence interval [CI]), and was calculated from admission until mortality from any cause within the study period. Patients were censored if they were alive at 60 days. Patients who were discharged home before day 60 were considered to be alive at day 60.

Survival curves were plotted using Kaplan–Meier methods. Log-rank tests were used to compare differences in survival. Time to successful discontinuation of mechanical ventilation was evaluated as described previously (Walkey and Wiener 2012).

Adjusted Cox regression modelling was performed using a stepwise selection of variables based on the Akaike information criterion. Variables that may have influenced clinical outcome included age, sex, serum albumin level, serum lactate dehydrogenase level, serum C-reactive protein level, McCabe and Jackson classification, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, \( \text{PaO}_2/\text{FiO}_2 \) ratio, white blood cell count, serum antithrombin III level, presence of cirrhosis, presence of pulmonary sepsis, Sequential Organ Failure
Assessment (SOFA) score, severity of ARDS based on the Berlin definition, disseminated intravascular coagulation (DIC) score, HRCT score of the lungs at admission, and azithromycin use. The DIC score was based on the DIC scoring system proposed by the Japanese Association for Acute Medicine (Gando et al. 2013). The HRCT score of the lungs was calculated as previously described (Ichikado et al. 2002).

We also estimated adjusted relationships between treatment and outcome using the Cox proportional hazards regression model via inverse probability of treatment weighting (IPTW) using a propensity score. The weights were based on the probability of receiving azithromycin. We used logistic regression models to estimate the propensity to receive azithromycin versus no azithromycin. The model included all variables mentioned above. All tests were two-sided and performed at a significance level of 0.05. We used the R statistical package (version 3.0.1; The R Foundation for Statistical Computing, Vienna, Austria) for all analyses.

**Results**

Initially, 185 patients with ARDS were identified, of whom 125 met the criteria for sepsis-associated ARDS. Baseline characteristics are shown in Table 1. Fifty-eight of 125 (46.4 %) patients died within 60 days.

Twenty-nine of 125 (23.2 %) patients with sepsis-associated ARDS were administered intravenous azithromycin within 24 h of an ARDS diagnosis. The median duration of azithromycin use after ARDS diagnosis was 5 days (IQR, 4–5 days); the mean duration was 4.4 ± 1.0 days. Table 2 shows a comparison of baseline characteristics between patients treated with azithromycin versus those who were not. There were 10 deaths (34.5 %) in the azithromycin group and 48 deaths (50 %) in the control group; the difference in survival was not significant (log-rank test; P = 0.167) (Fig. 1). There were significant differences between the two groups in the cause of ARDS (P = 0.048), PaO₂/FiO₂ ratio (P = 0.045), serum albumin level (P = 0.002), DIC score (P = 0.028), and platelet count (P = 0.003).

After adjustment for confounding covariates, azithromycin use was associated with lower mortality (adjusted hazard ratio [HR] 0.38; 95 % CI 0.18–0.79; P = 0.009) (Fig. 2).

In the adjusted analysis, APACHE II score (adjusted HR 1.09; 95 % CI 1.03–1.15; P = 0.004), CT score (adjusted HR 1.22; 95 % CI 1.10–1.35; P < 0.001; HR expressed as mortality change per 10 % increase in area of attenuation with traction bronchiectasis on HRCT), and DIC score (adjusted HR: 1.36; 95 % CI 1.17–1.59; P < 0.001) were also independently associated with a poor prognosis in the regression model (Table 3).

IPTW estimators with propensity score adjustment also showed that azithromycin use was associated with lower mortality (HR, 0.31; 95 % CI, 0.11–0.82; P = 0.02).

Time to successful discontinuation of mechanical ventilation was shorter in patients treated with azithromycin than in patients who were not (Fig. 3) (adjusted HR for successful ventilation discontinuation: 2.22; 95 % CI 1.24–3.99; P = 0.007).

**Discussion**

In this study, we observed lower mortality and a shorter duration of mechanical ventilation use in patients with sepsis-associated ARDS who received intravenous azithromycin within 24 h of sepsis-related ARDS diagnosis. We also identified associations between 60-day mortality, DIC score, and CT score in this cohort. Azithromycin use within 24 h of diagnosis was associated with improved outcomes in patients with sepsis-associated ARDS. Our result is consistent with Walkey's

### Table 1 Baseline characteristics of study

| Factor | Group | Overall |
|--------|-------|---------|
|        |       | N = 125 |
| Age, y |       | 75 [66, 82] |
| Sex    | M/F   | 85 [68.0]/40 (32.0) |
| Cirrhosis | No/Yes | 112 [89.6]/13 (10.4) |
| Sepsis | Pulmonary | 78 (62.4) |
|        | Nonpulmonary | 47 (37.6) |
| APACHE II |       | 23 [18, 27] |
| McCabe  | 1/2/3 | 114 [91.2]/5 [4.0]/5 (4.8) |
| ARDS severity | Mild | 10 (8.0) |
|        | Moderate | 58 (46.4) |
|        | Severe | 57 (45.6) |
| SOFA |       | 7 [5, 11] |
| PaO₂/FiO₂, mmHg |       | 106.80 [75.1, 139.7] |
| CT.score |       | 213.3 [184.8, 268.5] |
| Albumin, g/dL |       | 2.8 [2.40, 3.20] |
| WBC | 9600 [4200, 14,400] |
| C-reactive protein, mg/dL | 15.94 [9.01, 25.70] |
| Lactate dehydrogenase, IU/L | 308 [246, 434] |
| DIC score | 3 [2, 4] |
| FDP, mg/L | 11.10 [1.50, 170.70] |
| Antithrombin III % | 66.00 [52.00, 80.00] |
| Platelet, X10⁴ | 17.90 [10.10, 26.40] |
| D.dimer, μg/ml. | 5.60 [2.70, 11.00] |
| AZM use (%) | 29 (23.2) |
| Death (%) | 58 (46.4) |
report showing that macrolide use was associated with lower 180-day mortality (HR 0.46; 95% CI 0.23–0.92) (Walkey and Wiener 2012).

There are several reports of macrolide use leading to clinical benefits in patients with infection, especially in severe cases of pneumonia and sepsis (Restrepo et al. 2009; Kumar et al. 2010; Martin-Loeches et al. 2010; Sligl et al. 2014; Garin et al. 2014). Because sepsis is the most common cause of ARDS, macrolide use may lead to improved outcomes in sepsis-associated ARDS, but until now, there has been no evidence to support Walkey’s report. To our knowledge, this is the first report regarding the impact of a macrolide on mortality in patients with ARDS diagnosed by the Berlin definition.

We suggest that the survival benefit of azithromycin in sepsis-associated ARDS is due to anti-inflammatory and immunomodulating effects rather than antimicrobial activity. Walkey and Wiener also proposed that the anti-inflammatory and immunomodulatory effects of macrolides may benefit patients with acute lung injury (Walkey and Wiener 2012). Macrolides have been shown to prevent the production of pro-inflammatory mediators, cytokines, and reactive oxygen species (Kanoh and Rubin 2010), which is potentially the basis for their beneficial effects.

Pneumonia is the most common cause of ARDS. In our cohort, 62.4% of patients presented pneumonia. The current Infectious Diseases Society of America/American Thoracic Society guidelines for community-acquired pneumonia (CAP) (Mandell et al. 2007) recommend azithromycin use in patients with severe CAP requiring hospitalization on an intensive care unit. Our study supports the current recommendation. Early intervention with azithromycin may suppress excess inflammation that could lead to ARDS and multiple organ failure from severe pneumonia.

There are studies that found that macrolide use did not improve mortality from pneumonia (Asadi et al. 2012; Postma et al. 2015), but these studies included mild and severe forms of pneumonia.
moderate CAP that has low mortality, so a beneficial effect on mortality may not be detected easily. Another study found that macrolide use did not improve mortality in severe infection (Giamarellos-Bourboulis et al. 2014). A recent prospective randomized study assessing the efficacy of clarithromycin in patients with systemic inflammatory response syndrome due to acute pyelonephritis, acute intra-abdominal infection, or primary Gram-negative bacteraemia did not show an advantage in overall mortality (Giamarellos-Bourboulis et al. 2014).

However, researchers reported that clarithromycin use shortened the time to resolution of infection, especially in severe sepsis/shock patients, and decreased hospitalization cost. Further, a survival benefit was observed among patients with septic shock and multiple organ dysfunction syndrome in subgroup analyses (Giamarellos-Bourboulis et al. 2014).

Walkey reported that among patients with acute lung injury who were administered a macrolide, erythromycin...
was the most common (57%), followed by azithromycin (40%) (Walkey and Wiener 2012). Azithromycin is the only macrolide that was used in our study population, because azithromycin has fewer drug interactions and fewer side effects than erythromycin, and intravenous clarithromycin is not presently available in Japan. We selected an azithromycin course of 5 days based on a previously reported median duration of macrolide use of 4 days in acute lung injury (Walkey and Wiener 2012). We do not know if a 4–5 day course of a macrolide is long enough to develop favourable effects in patients with ARDS, or if there is a difference in optimal therapy duration between erythromycin and azithromycin, because they have quite different intracellular half-lives; azithromycin has a much longer half-life (40–68 h) than erythromycin. We also do not know whether an oral macrolide improves clinical outcomes in patients with sepsis-associated ARDS because of differing bioavailability.

In this study, we observed that the CT score and DIC score (meaning the presence of DIC) were useful independent prognostic factors for sepsis-associated ARDS. We had reported the utility of a CT score as a prognostic factor in ARDS (Ichikado et al. 2006, 2012), and that result has been reproduced in this study.

The DIC scoring system was proposed by the Japanese Association for Acute Medicine, and it has been reported that it exhibits good prognostic value in predicting multiple organ dysfunction syndrome and a poor prognosis in patients with severe sepsis (Gando et al. 2013). In this study, the DIC score was useful to assess prognosis in patients with sepsis-associated ARDS. Progression from ARDS to multiple organ failure was once thought to be caused by severe ARDS-induced hypoxemia. However, despite advances in respiratory care, many cases progress to multiple organ failure, the onset mechanisms of which are still unknown. Several investigators have previously reported patients with ARDS as having coagulopathy, both systemic and in the alveolar compartment (Bajaj and Tricomi 1999; Ware et al. 2003). Some studies have implicated activation of the coagulation cascade and impaired fibrinolytic activity as pathogeneses of pneumonia and acute lung injury (Gunther et al. 2000) (Schultz et al. 2006). Recently, several investigators have reported on the relationship between coagulopathy and proinflammatory events causing organ injury (Abraham 2000) (Coughlin 2000). Azithromycin has been reported to have immunomodulatory and anti-inflammatory activities, as well as anti-coagulant effects via platelet-activating factor mediated platelet aggregation (Tsourpas et al. 2011). From the viewpoint of coagulopathy in the pathogenesis of ARDS, azithromycin might have contributed to an improvement in survival in sepsis-associated DIC. Further study is needed to clarify the interaction between azithromycin and coagulopathy in ARDS.

Our study has several limitations. First, this study is from a single centre and is retrospective and observational in design. Patients with ARDS who were treated with azithromycin were included in this cohort recently, and there might have been improvements in supportive care over the 10 years that caused differences in outcomes between patients treated with a macrolide and those who were not (Additional file 1). Second, the sample size was small, especially in the azithromycin group, which greatly increases the risk of random error. We adjusted for overt biases by applying IPTW using propensity scores to resolve problems created by unequal chances of receiving treatment. However, we cannot rule out the possibility that unmeasured confounding factors might have affected our results. Because of these potential limitations, the data should be interpreted with caution. Third, the study only involved sepsis-associated ARDS, and therefore this result cannot be applied to ARDS caused by trauma, aspiration, or other factors. Fourth, we do not know valuable information about oral macrolide use before presentation. Fifth, this study did not contain a valuable microbial analysis.

Conclusions
In conclusion, we observed lower mortality and a shorter duration of mechanical ventilation in patients with sepsis-associated ARDS who received intravenous azithromycin within 24 h of ARDS diagnosis according to the Berlin definition. We also identified associations with 60-day mortality, DIC score, and CT score in this cohort. A further well-designed study is needed to determine whether azithromycin improves morality in sepsis-associated ARDS.

Additional file

Additional file 1. Trend of 60-day mortality from 2004 to 2015.

Authors’ contributions
All authors, with the exception of Dr. Suga, contributed to data collection and analysis. Dr. Kawamura is the main author of the paper and contributed to the design of the project, reviewed and analysed the study data, edited the main body of the manuscript, and contributed to approval of the final manuscript. Dr. Ichikado contributed to the design of the project, data interpretation, and editing and approval of the final manuscript. Dr. Suga contributed to data interpretation and preparation and approval of the final manuscript.

Acknowledgements
We thank Dr. Norihiro Iwamoto, Dr. Hiroyuki Muranaka, Dr. Yasuhiro Gushima, Dr. Naoko Arakawa, Dr. Mitsuko Honda, Dr. Tomoya Kuda, Dr. Shigeo Hiroshige, Dr. Azusa Katume, and Dr. Makiko Takeguchi for their clinical assistance.
Competing interests
The authors declare that they have no competing interests.

Received: 29 October 2015   Accepted: 19 July 2016
Published online: 28 July 2016

References
Abraham E (2000) Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 22(4):401–404
Amado-Rodriguez L, Gonzalez-Lopez A, Lopez-Alonso I, Aguirre A, Astudillo A, Batalla-Solis E et al (2013) Anti-inflammatory effects of clari-thromycin in ventilator-induced lung injury. Respir Res 14(1):52
Asadi L, Sigl W, Euriich DT, Colmers IN, Jepsjold L, Marrie TJ et al (2012) Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 55(3):371–380
Bajaj MS, Tricomo SM (1999) Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome. Intensive Care Med 25(11):1259–1266
Bernard G, Artigas A, Brigham K, Carlet J, Falke K, Hudson L et al (1994) The American-European consensus conference on ARDS Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655
Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407(6801):258–264
Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E et al (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307(23):2526–2533
Gando S, Saitoh D, Ogura H, Fujishima S, Mayumi T, Araki T et al (2013) Prediction of prognosis for acute respiratory distress syndrome. Am J Respir Crit Care Med 188(4):373–380
Giamarellos-Bourboulis EJ, Mylona V, Antonopoulou A, Tsangaris I, Koutelidakis I, Marioli A et al (2014) Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother 69(4):1111–1118
Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P et al (2005) In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards platelet activating factor and thrombin. Br J Pharmacol 141(1):17–27
Ichiikado K, Suga M, Muraoka H, Gushima Y, Miyakawa H, Tsubamoto M et al (2006) Prediction of prognosis for acute respiratory distress syndrome with thin-section CT. Validation in 44 cases. Radiology 238(1):321–329
Ichikado K, Muranaka H, Gushima Y, Kotani T, Nader HM, Fujimoto K et al (2012) Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study. BMJ Open 2(2):e000545
Kanoh S, Suga M, Müller NL, Taniguchi H, Kondoh Y, Akira M et al (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 44(Supplement 2):S27–S52
Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garmacho-Montero J et al (2010) Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36(4):612–620
Postma DF, van Werkhoven CH, van Elden LJ, Thijssen SFT, Hoepelman AIM, Kluymans JAW et al (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372(14):1312–1323
Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A (2009) Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 33(1):153–159
Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M et al (2005) Incidence and outcomes of acute lung injury. N Engl J Med 353(16):1685–1693
Sato K, Suga M, Akafe T, Fuji S, Muranaka MH (1998) Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 157(3 Pt 1):853–857
Schultz MJ, Haitsma JJ, Zhang H, Slutsy AS (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review. Crit Care Med 34(3):871–877
Sigl W, Asadi L, Euriich DT, Jepsjold L, Marrie TJ, Majumdar SR (2014) Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 42(2):420–432
Society JR (2010) Clinical practical guideline for acute lung injury and acute respiratory distress syndrome. Tamaoki J (2004) The effects of macrolides on inflammatory cells. Chest 125(2 Suppl):415–450 (quiz 15)
Tsopras A, Chini M, Tsogas N, Lioni A, Tsekes G, Demopoulos C et al (2011) In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards platelet activating factor and thrombin. J Inflamm 8(11):17
Ware LB, Fang X, Matthay MA (2003) Protein C and thrombomodulin in human acute lung injury. Am J Respir Cell Mol Biol 22(4):401–404
Werle LB, Fang X, Matthay MA (2003) Protein C and thrombomodulin in human acute lung injury. Am J Respir Cell Mol Biol 22(4):401–404
Wetmore JD, Brusilow SW (2001) Coagulation abnormalities in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 281(3):L578–L585
Yoshizawa T, Sada A, Sakai T, Hata K, Iwata K, Matsumoto S et al (2016) Vitamin D3 reduces lung injury in sepsis via suppression of the pro-inflammatory response. J Inflamm (Lond) 13(1):12
Zambon M, Vincent JL (2008) Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 133(5):1120–1127

месеното за субмит на вашиот труд до SpringerOpen™ портала за научни претпоставки и корисности од: 

► Convenient online submission
► Rigorous peer review
► Immediate publication on acceptance
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com